Intervention: Tixagevimab/Cilgavimab

DisCoVeRy

Austria Belgium France Greece Luxembourg Norway Portugal
|
2020-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Remdesivir
  • Tixagevimab/Cilgavimab
  • Hydroxychloroquine
  • Interferon Beta-1A
  • Lopinavir/ritonavir

Pinchera

Italy
|
2023-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Infectious diseases unit
  • SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies
  • Tixagevimab/Cilgavimab

Orth

Germany
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Remdesivir
  • Nirmatrelvir/Ritonavir
  • Molnupiravir
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Huygens

The Netherlands
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Colaneri 2

Italy
|
2021-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Remdesivir
  • Nirmatrelvir/Ritonavir
  • Molnupiravir
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab
  • Bamlanivimab/ Etesevimab

CoCoPrev

France
|
2021-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Perrotta

Italy
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • Emergency department
  • Infectious diseases unit
  • SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab
  • Bamlanivimab/ Etesevimab

Rotundo

Italy
|
2022-2023
  • Adults (18-64 years)
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Remdesivir
  • Nirmatrelvir/Ritonavir
  • Molnupiravir
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Nguyen

France
|
2021-2022
  • Adults (18-64 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies
  • Tixagevimab/Cilgavimab